跳转至内容
Merck
  • Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.

Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.

PloS one (2014-09-13)
Veerle W Daniëls, Karine Smans, Ines Royaux, Melanie Chypre, Johannes V Swinnen, Nousheen Zaidi
摘要

Increased lipogenesis is a hallmark of a wide variety of cancers and is under intense investigation as potential antineoplastic target. Although brisk lipogenesis is observed in the presence of exogenous lipids, evidence is mounting that these lipids may adversely affect the efficacy of inhibitors of lipogenic pathways. Therefore, to fully exploit the therapeutic potential of lipid synthesis inhibitors, a better understanding of the interrelationship between de novo lipid synthesis and exogenous lipids and their respective role in cancer cell proliferation and therapeutic response to lipogenesis inhibitors is of critical importance. Here, we show that the proliferation of various cancer cell lines (PC3M, HepG2, HOP62 and T24) is attenuated when cultured in lipid-reduced conditions in a cell line-dependent manner, with PC3M being the least affected. Interestingly, all cell lines--lipogenic (PC3M, HepG2, HOP62) as well as non-lipogenic (T24)--raised their lipogenic activity in these conditions, albeit to a different degree. Cells that attained the highest lipogenic activity under these conditions were best able to cope with lipid reduction in term of proliferative capacity. Supplementation of the medium with very low density lipoproteins, free fatty acids and cholesterol reversed this activation, indicating that the mere lack of lipids is sufficient to activate de novo lipogenesis in cancer cells. Consequently, cancer cells grown in lipid-reduced conditions became more dependent on de novo lipid synthesis pathways and were more sensitive to inhibitors of lipogenic pathways, like Soraphen A and Simvastatin. Collectively, these data indicate that limitation of access to exogenous lipids, as may occur in intact tumors, activates de novo lipogenesis is cancer cells, helps them to thrive under these conditions and makes them more vulnerable to lipogenesis inhibitors. These observations have important implications for the design of new antineoplastic strategies targeting the cancer cell's lipid metabolism.

材料
货号
品牌
产品描述

Sigma-Aldrich
台盼蓝 溶液, 0.4%, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
胆固醇, Sigma Grade, ≥99%
Sigma-Aldrich
胆固醇, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
胆固醇, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
台盼蓝, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
辛伐他汀, ≥97% (HPLC), solid
Sigma-Aldrich
SyntheChol ® NS0 补充, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
SAFC
胆固醇、植物的, SyntheChol®
Supelco
胆固醇 溶液, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
台盼蓝, Dye content 60 %, ≥80% (HPLC)
Sigma-Aldrich
三亚油酸甘油酯, ≥98% (TLC), liquid
Sigma-Aldrich
台盼蓝 溶液, 0.4%, for microscopy
Supelco
胆固醇, Pharmaceutical Secondary Standard; Certified Reference Material
USP
辛伐他汀, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
三亚麻酸甘油酯, ≥97% (TLC), liquid
SAFC
胆固醇, from sheep wool, Controlled origin, meets USP/NF testing specifications
Supelco
辛伐他汀, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胆固醇, tested according to Ph. Eur.
辛伐他汀, European Pharmacopoeia (EP) Reference Standard
Supelco
三亚油酸甘油酯, analytical standard
Supelco
辛伐他汀, analytical standard